CN107110861A - 作为诊断性生物标志物的抗淋巴细胞的自身抗体 - Google Patents

作为诊断性生物标志物的抗淋巴细胞的自身抗体 Download PDF

Info

Publication number: CN107110861A
Authority: CN; China
Prior art keywords: lymphocytes; individual; level; autoantibody; cells
Prior art date: 2014-08-08
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Pending

Application number

CN201580053913.2A

Other languages

English (en)

Chinese (zh)

Inventor

J·M·埃亨

C－C·刘

S·M·曼兹

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Allegheny Singer Research Institute

Original Assignee

Allegheny Singer Research Institute

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2014-08-08

Filing date

2015-08-07

Publication date

2017-08-29

2015-08-07 Application filed by Allegheny Singer Research Institute filed Critical Allegheny Singer Research Institute

2017-08-29 Publication of CN107110861A publication Critical patent/CN107110861A/zh

Status Pending legal-status Critical Current

Links

239000000104 diagnostic biomarker Substances 0.000 title claims description 18
230000000781 anti-lymphocytic effect Effects 0.000 title description 5
210000004027 cell Anatomy 0.000 claims abstract description 130
238000000034 method Methods 0.000 claims abstract description 67
210000004369 blood Anatomy 0.000 claims abstract description 53
239000008280 blood Substances 0.000 claims abstract description 53
210000000265 leukocyte Anatomy 0.000 claims abstract description 20
230000009885 systemic effect Effects 0.000 claims abstract description 9
239000003814 drug Substances 0.000 claims abstract description 6
230000000527 lymphocytic effect Effects 0.000 claims abstract 19
210000001744 T-lymphocyte Anatomy 0.000 claims description 162
201000000596 systemic lupus erythematosus Diseases 0.000 claims description 138
210000004698 lymphocyte Anatomy 0.000 claims description 58
230000024203 complement activation Effects 0.000 claims description 35
206010025135 lupus erythematosus Diseases 0.000 claims description 33
208000027866 inflammatory disease Diseases 0.000 claims description 30
230000008021 deposition Effects 0.000 claims description 23
239000003153 chemical reaction reagent Substances 0.000 claims description 20
238000000684 flow cytometry Methods 0.000 claims description 20
231100000433 cytotoxic Toxicity 0.000 claims description 14
230000001472 cytotoxic effect Effects 0.000 claims description 14
238000003745 diagnosis Methods 0.000 claims description 9
238000003860 storage Methods 0.000 claims description 6
108050005493 CD3 protein, epsilon/gamma/delta subunit Proteins 0.000 claims description 5
101000716102 Homo sapiens T-cell surface glycoprotein CD4 Proteins 0.000 claims description 5
230000001413 cellular effect Effects 0.000 claims description 5
102100037853 C-C chemokine receptor type 4 Human genes 0.000 claims description 4
101710149863 C-C chemokine receptor type 4 Proteins 0.000 claims description 4
102100025074 C-C chemokine receptor-like 2 Human genes 0.000 claims description 4
102100028990 C-X-C chemokine receptor type 3 Human genes 0.000 claims description 4
102100031658 C-X-C chemokine receptor type 5 Human genes 0.000 claims description 4
102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 claims description 4
101000716068 Homo sapiens C-C chemokine receptor type 6 Proteins 0.000 claims description 4
101000916050 Homo sapiens C-X-C chemokine receptor type 3 Proteins 0.000 claims description 4
101000922405 Homo sapiens C-X-C chemokine receptor type 5 Proteins 0.000 claims description 4
101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 claims description 4
101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 claims description 4
101000946843 Homo sapiens T-cell surface glycoprotein CD8 alpha chain Proteins 0.000 claims description 4
102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 claims description 4
102100034922 T-cell surface glycoprotein CD8 alpha chain Human genes 0.000 claims description 4
239000003550 marker Substances 0.000 claims description 4
YCKRFDGAMUMZLT-UHFFFAOYSA-N Fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 claims description 3
229910052731 fluorine Inorganic materials 0.000 claims description 3
239000011737 fluorine Substances 0.000 claims description 3
239000000203 mixture Substances 0.000 claims 6
239000007850 fluorescent dye Substances 0.000 claims 5
238000001215 fluorescent labelling Methods 0.000 claims 5
210000002751 lymph Anatomy 0.000 claims 2
108010078018 Complement C3d Proteins 0.000 claims 1
102100027268 Interferon-stimulated gene 20 kDa protein Human genes 0.000 claims 1
230000015572 biosynthetic process Effects 0.000 claims 1
230000001052 transient effect Effects 0.000 claims 1
239000000523 sample Substances 0.000 description 45
229920008347 Cellulose acetate propionate Polymers 0.000 description 38
238000009470 controlled atmosphere packaging Methods 0.000 description 38
210000002381 plasma Anatomy 0.000 description 32
210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 31
239000000090 biomarker Substances 0.000 description 27
201000010099 disease Diseases 0.000 description 25
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 25
229940027941 immunoglobulin g Drugs 0.000 description 20
238000012544 monitoring process Methods 0.000 description 18
238000003556 assay Methods 0.000 description 11
230000007246 mechanism Effects 0.000 description 11
238000012546 transfer Methods 0.000 description 11
230000004913 activation Effects 0.000 description 10
108060003951 Immunoglobulin Proteins 0.000 description 9
239000003795 chemical substances by application Substances 0.000 description 9
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 9
102000018358 immunoglobulin Human genes 0.000 description 9
238000000338 in vitro Methods 0.000 description 9
230000008506 pathogenesis Effects 0.000 description 9
239000002953 phosphate buffered saline Substances 0.000 description 9
210000000662 T-lymphocyte subset Anatomy 0.000 description 8
230000009266 disease activity Effects 0.000 description 8
230000035945 sensitivity Effects 0.000 description 8
210000002966 serum Anatomy 0.000 description 8
238000005259 measurement Methods 0.000 description 7
101100262440 Arabidopsis thaliana ECR1 gene Proteins 0.000 description 6
108010034753 Complement Membrane Attack Complex Proteins 0.000 description 6
-1 DAF Proteins 0.000 description 6
238000002474 experimental method Methods 0.000 description 6
238000001727 in vivo Methods 0.000 description 6
210000001616 monocyte Anatomy 0.000 description 6
238000010186 staining Methods 0.000 description 6
206010025327 Lymphopenia Diseases 0.000 description 5
230000004154 complement system Effects 0.000 description 5
231100001023 lymphopenia Toxicity 0.000 description 5
238000004519 manufacturing process Methods 0.000 description 5
230000008569 process Effects 0.000 description 5
238000012360 testing method Methods 0.000 description 5
208000023275 Autoimmune disease Diseases 0.000 description 4
108010004729 Phycoerythrin Proteins 0.000 description 4
230000002159 abnormal effect Effects 0.000 description 4
210000001772 blood platelet Anatomy 0.000 description 4
238000005119 centrifugation Methods 0.000 description 4
208000037976 chronic inflammation Diseases 0.000 description 4
230000000295 complement effect Effects 0.000 description 4
230000000875 corresponding effect Effects 0.000 description 4
210000003743 erythrocyte Anatomy 0.000 description 4
210000002443 helper t lymphocyte Anatomy 0.000 description 4
210000005259 peripheral blood Anatomy 0.000 description 4
239000011886 peripheral blood Substances 0.000 description 4
238000011002 quantification Methods 0.000 description 4
208000017667 Chronic Disease Diseases 0.000 description 3
208000035473 Communicable disease Diseases 0.000 description 3
102100026878 Interleukin-2 receptor subunit alpha Human genes 0.000 description 3
201000002481 Myositis Diseases 0.000 description 3
206010039710 Scleroderma Diseases 0.000 description 3
208000021386 Sjogren Syndrome Diseases 0.000 description 3
208000025851 Undifferentiated connective tissue disease Diseases 0.000 description 3
208000017379 Undifferentiated connective tissue syndrome Diseases 0.000 description 3
238000000540 analysis of variance Methods 0.000 description 3
238000004458 analytical method Methods 0.000 description 3
210000003719 b-lymphocyte Anatomy 0.000 description 3
210000000601 blood cell Anatomy 0.000 description 3
208000037893 chronic inflammatory disorder Diseases 0.000 description 3
210000003040 circulating cell Anatomy 0.000 description 3
230000006378 damage Effects 0.000 description 3
230000004064 dysfunction Effects 0.000 description 3
230000000694 effects Effects 0.000 description 3
230000003325 follicular Effects 0.000 description 3
208000013643 idiopathic inflammatory myopathy Diseases 0.000 description 3
238000011534 incubation Methods 0.000 description 3
208000015181 infectious disease Diseases 0.000 description 3
230000004968 inflammatory condition Effects 0.000 description 3
238000002372 labelling Methods 0.000 description 3
230000001404 mediated effect Effects 0.000 description 3
230000001717 pathogenic effect Effects 0.000 description 3
208000012934 primary antiphospholipid syndrome Diseases 0.000 description 3
108090000623 proteins and genes Proteins 0.000 description 3
102000004169 proteins and genes Human genes 0.000 description 3
238000000746 purification Methods 0.000 description 3
230000001105 regulatory effect Effects 0.000 description 3
238000011160 research Methods 0.000 description 3
206010039073 rheumatoid arthritis Diseases 0.000 description 3
208000024172 Cardiovascular disease Diseases 0.000 description 2
201000005569 Gout Diseases 0.000 description 2
206010072579 Granulomatosis with polyangiitis Diseases 0.000 description 2
206010061218 Inflammation Diseases 0.000 description 2
201000001263 Psoriatic Arthritis Diseases 0.000 description 2
208000036824 Psoriatic arthropathy Diseases 0.000 description 2
208000003782 Raynaud disease Diseases 0.000 description 2
208000012322 Raynaud phenomenon Diseases 0.000 description 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
206010052779 Transplant rejections Diseases 0.000 description 2
206010047115 Vasculitis Diseases 0.000 description 2
208000033017 acquired idiopathic inflammatory myopathy Diseases 0.000 description 2
239000012190 activator Substances 0.000 description 2
230000001154 acute effect Effects 0.000 description 2
108010004469 allophycocyanin Proteins 0.000 description 2
230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 2
239000003146 anticoagulant agent Substances 0.000 description 2
229940127219 anticoagulant drug Drugs 0.000 description 2
239000000427 antigen Substances 0.000 description 2
102000036639 antigens Human genes 0.000 description 2
108091007433 antigens Proteins 0.000 description 2
230000002051 biphasic effect Effects 0.000 description 2
239000000872 buffer Substances 0.000 description 2
230000001364 causal effect Effects 0.000 description 2
230000006037 cell lysis Effects 0.000 description 2
239000002458 cell surface marker Substances 0.000 description 2
210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 2
238000001514 detection method Methods 0.000 description 2
239000012634 fragment Substances 0.000 description 2
230000006870 function Effects 0.000 description 2
230000014509 gene expression Effects 0.000 description 2
210000003714 granulocyte Anatomy 0.000 description 2
208000010710 hepatitis C virus infection Diseases 0.000 description 2
229940072221 immunoglobulins Drugs 0.000 description 2
230000004054 inflammatory process Effects 0.000 description 2
238000002955 isolation Methods 0.000 description 2
108010026228 mRNA guanylyltransferase Proteins 0.000 description 2
210000002540 macrophage Anatomy 0.000 description 2
230000004048 modification Effects 0.000 description 2
238000012986 modification Methods 0.000 description 2
201000006417 multiple sclerosis Diseases 0.000 description 2
210000000822 natural killer cell Anatomy 0.000 description 2
239000013642 negative control Substances 0.000 description 2
230000003287 optical effect Effects 0.000 description 2
201000008482 osteoarthritis Diseases 0.000 description 2
208000018036 overlapping connective tissue disease Diseases 0.000 description 2
230000037361 pathway Effects 0.000 description 2
230000003389 potentiating effect Effects 0.000 description 2
201000011461 pre-eclampsia Diseases 0.000 description 2
230000035935 pregnancy Effects 0.000 description 2
238000002360 preparation method Methods 0.000 description 2
102000005962 receptors Human genes 0.000 description 2
108020003175 receptors Proteins 0.000 description 2
210000001995 reticulocyte Anatomy 0.000 description 2
229960004641 rituximab Drugs 0.000 description 2
206010040400 serum sickness Diseases 0.000 description 2
208000007056 sickle cell anemia Diseases 0.000 description 2
239000000243 solution Substances 0.000 description 2
230000008685 targeting Effects 0.000 description 2
230000000451 tissue damage Effects 0.000 description 2
231100000827 tissue damage Toxicity 0.000 description 2
102100032957 C5a anaphylatoxin chemotactic receptor 1 Human genes 0.000 description 1
101710098483 C5a anaphylatoxin chemotactic receptor 1 Proteins 0.000 description 1
102100022002 CD59 glycoprotein Human genes 0.000 description 1
VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 1
108010067641 Complement C3-C5 Convertases Proteins 0.000 description 1
102000016574 Complement C3-C5 Convertases Human genes 0.000 description 1
108010078015 Complement C3b Proteins 0.000 description 1
102100025877 Complement component C1q receptor Human genes 0.000 description 1
102100030886 Complement receptor type 1 Human genes 0.000 description 1
102100032768 Complement receptor type 2 Human genes 0.000 description 1
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
229920001917 Ficoll Polymers 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
101000897400 Homo sapiens CD59 glycoprotein Proteins 0.000 description 1
101100275686 Homo sapiens CR2 gene Proteins 0.000 description 1
101000933665 Homo sapiens Complement component C1q receptor Proteins 0.000 description 1
101000727061 Homo sapiens Complement receptor type 1 Proteins 0.000 description 1
101001055956 Homo sapiens Mannan-binding lectin serine protease 1 Proteins 0.000 description 1
101001056015 Homo sapiens Mannan-binding lectin serine protease 2 Proteins 0.000 description 1
101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 1
102100026061 Mannan-binding lectin serine protease 1 Human genes 0.000 description 1
102100026046 Mannan-binding lectin serine protease 2 Human genes 0.000 description 1
101100275687 Mus musculus Cr2 gene Proteins 0.000 description 1
102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
210000003651 basophil Anatomy 0.000 description 1
239000011324 bead Substances 0.000 description 1
230000008901 benefit Effects 0.000 description 1
230000033228 biological regulation Effects 0.000 description 1
210000004204 blood vessel Anatomy 0.000 description 1
230000000981 bystander Effects 0.000 description 1
239000006285 cell suspension Substances 0.000 description 1
230000005889 cellular cytotoxicity Effects 0.000 description 1
230000007248 cellular mechanism Effects 0.000 description 1
230000005754 cellular signaling Effects 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
230000001684 chronic effect Effects 0.000 description 1
230000006020 chronic inflammation Effects 0.000 description 1
210000002358 circulating endothelial cell Anatomy 0.000 description 1
108010052926 complement C3d,g Proteins 0.000 description 1
230000009850 completed effect Effects 0.000 description 1
239000012141 concentrate Substances 0.000 description 1
239000013068 control sample Substances 0.000 description 1
230000002596 correlated effect Effects 0.000 description 1
238000010219 correlation analysis Methods 0.000 description 1
210000004748 cultured cell Anatomy 0.000 description 1
230000001086 cytosolic effect Effects 0.000 description 1
230000003013 cytotoxicity Effects 0.000 description 1
231100000135 cytotoxicity Toxicity 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
230000007547 defect Effects 0.000 description 1
230000007123 defense Effects 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
239000010432 diamond Substances 0.000 description 1
230000004069 differentiation Effects 0.000 description 1
229940079593 drug Drugs 0.000 description 1
210000003979 eosinophil Anatomy 0.000 description 1
210000002950 fibroblast Anatomy 0.000 description 1
239000012997 ficoll-paque Substances 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
230000036541 health Effects 0.000 description 1
230000003862 health status Effects 0.000 description 1
208000007475 hemolytic anemia Diseases 0.000 description 1
230000009390 immune abnormality Effects 0.000 description 1
230000008938 immune dysregulation Effects 0.000 description 1
230000028993 immune response Effects 0.000 description 1
208000026278 immune system disease Diseases 0.000 description 1
230000006872 improvement Effects 0.000 description 1
238000000099 in vitro assay Methods 0.000 description 1
230000003993 interaction Effects 0.000 description 1
108040006849 interleukin-2 receptor activity proteins Proteins 0.000 description 1
239000003446 ligand Substances 0.000 description 1
230000007774 longterm Effects 0.000 description 1
230000002101 lytic effect Effects 0.000 description 1
239000000463 material Substances 0.000 description 1
210000003593 megakaryocyte Anatomy 0.000 description 1
230000009456 molecular mechanism Effects 0.000 description 1
229940126619 mouse monoclonal antibody Drugs 0.000 description 1
230000003472 neutralizing effect Effects 0.000 description 1
210000000440 neutrophil Anatomy 0.000 description 1
210000000056 organ Anatomy 0.000 description 1
238000012261 overproduction Methods 0.000 description 1
244000052769 pathogen Species 0.000 description 1
210000005105 peripheral blood lymphocyte Anatomy 0.000 description 1
210000004180 plasmocyte Anatomy 0.000 description 1
238000013105 post hoc analysis Methods 0.000 description 1
238000010149 post-hoc-test Methods 0.000 description 1
238000011533 pre-incubation Methods 0.000 description 1
230000006337 proteolytic cleavage Effects 0.000 description 1
230000009467 reduction Effects 0.000 description 1
230000004044 response Effects 0.000 description 1
230000002441 reversible effect Effects 0.000 description 1
238000012552 review Methods 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
210000000130 stem cell Anatomy 0.000 description 1
238000013517 stratification Methods 0.000 description 1
239000000725 suspension Substances 0.000 description 1
208000011580 syndromic disease Diseases 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
150000007970 thio esters Chemical group 0.000 description 1
210000001519 tissue Anatomy 0.000 description 1
230000007704 transition Effects 0.000 description 1
230000001960 triggered effect Effects 0.000 description 1

Classifications

- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5047—Cells of the immune system
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5047—Cells of the immune system
- G01N33/505—Cells of the immune system involving T-cells
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5047—Cells of the immune system
- G01N33/5052—Cells of the immune system involving B-cells
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5047—Cells of the immune system
- G01N33/5055—Cells of the immune system involving macrophages
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/536—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
- G01N2333/7051—T-cell receptor (TcR)-CD3 complex
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
- G01N2333/70514—CD4
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
- G01N2333/70517—CD8
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/10—Musculoskeletal or connective tissue disorders
- G01N2800/101—Diffuse connective tissue disease, e.g. Sjögren, Wegener's granulomatosis
- G01N2800/104—Lupus erythematosus [SLE]
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/70—Mechanisms involved in disease identification
- G01N2800/7095—Inflammation

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Immunology (AREA)
Engineering & Computer Science (AREA)
Biomedical Technology (AREA)
Hematology (AREA)
Chemical & Material Sciences (AREA)
Urology & Nephrology (AREA)
Molecular Biology (AREA)
Cell Biology (AREA)
General Physics & Mathematics (AREA)
Biochemistry (AREA)
Biotechnology (AREA)
Pathology (AREA)
General Health & Medical Sciences (AREA)
Food Science & Technology (AREA)
Medicinal Chemistry (AREA)
Physics & Mathematics (AREA)
Analytical Chemistry (AREA)
Microbiology (AREA)
Toxicology (AREA)
Bioinformatics & Cheminformatics (AREA)
Tropical Medicine & Parasitology (AREA)
Rehabilitation Therapy (AREA)
Rheumatology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Investigating Or Analysing Biological Materials (AREA)
Peptides Or Proteins (AREA)

CN201580053913.2A 2014-08-08 2015-08-07 作为诊断性生物标志物的抗淋巴细胞的自身抗体 Pending CN107110861A (zh)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US201462035073P	2014-08-08	2014-08-08
US62/035,073		2014-08-08
PCT/US2015/044372 WO2016023006A1 (en)	2014-08-08	2015-08-07	Anti-lymphocyte autoantibodies as diagnostic biomarkers

Publications (1)

Publication Number	Publication Date
CN107110861A true CN107110861A (zh)	2017-08-29

Family

ID=55264686

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CN201580053913.2A Pending CN107110861A (zh)	2014-08-08	2015-08-07	作为诊断性生物标志物的抗淋巴细胞的自身抗体

Country Status (7)

Country	Link
US (1)	US9709564B2 (2)
EP (1)	EP3177930A1 (2)
JP (1)	JP2017528734A (2)
CN (1)	CN107110861A (2)
BR (1)	BR112017002575B1 (2)
RU (1)	RU2017107273A (2)
WO (1)	WO2016023006A1 (2)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US10067128B2 (en)	2015-07-31	2018-09-04	Allegheny-Singer Research Institute	Cell-bound complement activation product assays as companion diagnostics for antibody-based drugs
KR101674018B1 (ko) *	2016-05-16	2016-11-08	(주)글로리바이오텍	Cd4, cd8 세포 정보를 이용한 hiv 진단 방법
AU2017269968B2 (en)	2016-05-24	2024-02-01	Allegheny-Singer Research Institute	Methods and systems using C4 gene copy number and cell-bound complement activation products for identification of lupus and pre-lupus
CA3170448A1 (en) *	2020-09-28	2022-03-31	Joseph M. Ahearn	Methods for determining a level of a cell fragment-bound complement activation product

Citations (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2005108988A2 (en) *	2004-04-09	2005-11-17	University Of Pittsburgh	Real time method of detecting acute inflammatory conditions
WO2011099012A1 (en) *	2010-02-12	2011-08-18	Yeda Research And Development Co. Ltd.	Diagnosis of systemic lupus erythematosus (sle)
WO2012109592A1 (en) *	2011-02-11	2012-08-16	Exagen Diagnostics, Inc.	Methods for diagnosing systemic lupus erythematosus
CN102818890A (zh) *	2011-06-10	2012-12-12	苏州卫生职业技术学院	一种检测系统性红斑狼疮患者自身抗体的方法
CN103439517A (zh) *	2013-09-11	2013-12-11	河北省健海生物芯片技术有限责任公司	一种系统性红斑狼疮自身抗体检测装置

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DK1745287T3 (da) *	2004-05-11	2011-01-24	Univ Pittsburgh	Diagnostisering og monitorering af inflammatoriske sygdomme ved at måle komplementkomponenter på hvide blodlegemer
AU2009305575A1 (en) *	2008-10-16	2010-04-22	Cypress Bioscience, Inc.	Method for diagnosis and monitoring of disease activity and response to treatment in systemic lupus erythematosus (SLE) and other autoimmune diseases
US9075069B2 (en) *	2011-12-13	2015-07-07	Baxter International Inc.	Measurement of autoantibodies at low conductivity with increased sensitivity
EP2880445A1 (en)	2012-08-02	2015-06-10	Sense Proteomic Limited	Auto-antigen biomarkers for lupus
WO2014093268A1 (en)	2012-12-10	2014-06-19	Allegheny-Singer Research Institute	Methods and systems for using complement-tagged molecules as biomarkers of disease
RU2680270C2 (ru)	2013-02-08	2019-02-19	Аллегени-Сингер Рисерч Инститьют	Клеточно-связанные продукты активации комплемента в качестве диагностических биомаркеров волчанки в доклинической стадии

2015
- 2015-08-07 WO PCT/US2015/044372 patent/WO2016023006A1/en not_active Ceased
- 2015-08-07 BR BR112017002575-2A patent/BR112017002575B1/pt active IP Right Grant
- 2015-08-07 CN CN201580053913.2A patent/CN107110861A/zh active Pending
- 2015-08-07 JP JP2017527543A patent/JP2017528734A/ja active Pending
- 2015-08-07 US US14/821,670 patent/US9709564B2/en active Active
- 2015-08-07 RU RU2017107273A patent/RU2017107273A/ru not_active Application Discontinuation
- 2015-08-07 EP EP15754066.7A patent/EP3177930A1/en not_active Withdrawn

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2005108988A2 (en) *	2004-04-09	2005-11-17	University Of Pittsburgh	Real time method of detecting acute inflammatory conditions
WO2011099012A1 (en) *	2010-02-12	2011-08-18	Yeda Research And Development Co. Ltd.	Diagnosis of systemic lupus erythematosus (sle)
WO2012109592A1 (en) *	2011-02-11	2012-08-16	Exagen Diagnostics, Inc.	Methods for diagnosing systemic lupus erythematosus
CN102818890A (zh) *	2011-06-10	2012-12-12	苏州卫生职业技术学院	一种检测系统性红斑狼疮患者自身抗体的方法
CN103439517A (zh) *	2013-09-11	2013-12-11	河北省健海生物芯片技术有限责任公司	一种系统性红斑狼疮自身抗体检测装置

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
CHAU-CHING LIU ET AL.: "Antilymphocyte autoantibodies generate T cell–C4d signatures in systemic lupus erythematosus", 《TRANSLATIONAL RESEARCH》 *

Also Published As

Publication number	Publication date
US9709564B2 (en)	2017-07-18
BR112017002575B1 (pt)	2023-11-07
BR112017002575A2 (pt)	2018-01-30
RU2017107273A (ru)	2018-09-10
EP3177930A1 (en)	2017-06-14
WO2016023006A1 (en)	2016-02-11
RU2017107273A3 (2)	2019-01-18
US20160041164A1 (en)	2016-02-11
JP2017528734A (ja)	2017-09-28

Legal Events

Date	Code	Title	Description
2017-08-29	PB01	Publication
2017-08-29	PB01	Publication
2017-09-22	SE01	Entry into force of request for substantive examination
2017-09-22	SE01	Entry into force of request for substantive examination
2018-12-25	WD01	Invention patent application deemed withdrawn after publication	Application publication date: 20170829
2018-12-25	WD01	Invention patent application deemed withdrawn after publication

Publication	Publication Date	Title
US11796547B2 (en)	2023-10-24	Methods of detecting donor-specific antibodies and systems for practicing the same
CN105866426B (zh)	2018-11-23	用于检测补体结合性抗体的方法和组合物
CN108375676B (zh)	2022-01-07	从血液中捕获和检测循环多发性骨髓瘤的测定法
EP2726883A1 (en)	2014-05-07	A cell mediated immune response assay with enhanced sensitivity
US20240168025A1 (en)	2024-05-23	Hematopoietic cell phenotyping using circulating cell-free markers
CN107110861A (zh)	2017-08-29	作为诊断性生物标志物的抗淋巴细胞的自身抗体
CN114341644A (zh)	2022-04-12	鉴定促炎树突细胞的方法
Vitales-Noyola et al.	2022	Levels of pathogenic Th17 and Th22 cells in patients with rheumatoid arthritis
JP2007537449A (ja)	2007-12-20	白血球上の補体成分を測定することによる炎症性疾患の診断およびモニタリング
WO2014160376A1 (en)	2014-10-02	Methods of detecting complement fixing and non-complement fixing antibodies and systems for practicing the same
CN105051210B (zh)	2020-07-28	细胞结合的补体激活产物作为狼疮前期的诊断性生物标志物
JP7193054B2 (ja)	2022-12-20	自己免疫疾患の臨床転帰を評価するための方法及びキット
Liu et al.	2014	Antilymphocyte autoantibodies generate T cell–C4d signatures in systemic lupus erythematosus
Kljajić	2023	Impact of Covid-19 on HLA antibody profile in renal transplant recipients
Forconi et al.	2026	EBV Type 1 versus Type 2: A determinant of NK cell anti-tumor activity in Burkitt lymphoma
Drawy et al.	2018	T-cell markers in systemic lupus erythromatosus patients
Ibrahim et al.	2015	Increased soluble HLA-DRB1 in B-cell acute lymphoblastic leukaemia
EP3341738A1 (en)	2018-07-04	Methods and compositions for the detection of fc receptor binding activity of antibodies
WO2013045672A1 (en)	2013-04-04	A method for predicting the responsiveness a patient to a treatment with an il-6 antagonist
Clarke	2009	Endothelial injury and repair in vasculitis of the young
Bachmann et al.	2014	Affinity Proteomics Reveals Elevated Muscle Proteins in Plasma of Children with
Tsokos	2011	T Cell Lipid Rafts and Complement Ligands for Diagnosis and Monitoring of SLE